Boston, Massachusetts 02215


Purpose:

The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese. Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss. The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.


Criteria:

Inclusion Criteria: 1. Type 2 diabetes 2. BMI 25-45 kg/m2 3. Hemoglobin A1C > 6.5% but < 9% 4. Normal renal function (GFR > 60) 5. Age 18-75 Exclusion Criteria: 1. Type 1 diabetes 2. History of recurrent UTI or mycotic genital infections 3. Treatment with insulin or a GLP1 agent 4. Pregnant or breastfeeding


NCT ID:

NCT02360774


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02215
United States

Jody Dushay, MD
Phone: 617-667-1996
Email: jdushay@bidmc.harvard.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.